Protein / target

DNA topoisomerase 4 subunit B

parEQ59961Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)Swiss-Prot
UniProt: Q59961
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

DNA negative supercoiling activity

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule

Domains and Gene Ontology detail (8)

Domains & features

Toprim

Gene Ontology

  • Cchromosome
  • FATP binding
  • FDNA binding
  • FDNA negative supercoiling activity
  • Fmetal ion binding
  • Pchromosome segregation
  • PDNA topological change

647 aa · 72 kDa

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Levofloxacin
Inhibitor

Topoisomerase IV inhibitor

Acts on a complex — shared with parC · 1 of 4 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in AdultsPHASE3

COMPLETED · via Levofloxacin · NCT00236821

Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell TransplantationPHASE1/PHASE2

UNKNOWN · via Levofloxacin · NCT02148016

TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot StudyPHASE4

TERMINATED · via Levofloxacin · NCT00239161

Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated TuberculosisPHASE3

ACTIVE_NOT_RECRUITING · via Levofloxacin · NCT04951986

Comparison of Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized TrialPHASE4

UNKNOWN · via Levofloxacin · NCT03555526

A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Cefuroxime Axetil in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in AdultsPHASE3

COMPLETED · via Levofloxacin · NCT00269932

Show remaining trials (24)
Comparing the Efficacy of Two Weeks Therapy of Doxycycline,Levofloxacin,Tinidazole Versus Levofloxacin With Tinidazole on Rate of Eradication of Helicobacter Pylori Infected Patients on Syrian PopulationPHASE4

UNKNOWN · via Levofloxacin · NCT04626193

Topical Antibiotics in Chronic RhinosinusitisPHASE1/PHASE2

COMPLETED · via Levofloxacin · NCT03673956

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)PHASE4

COMPLETED · via Levofloxacin · NCT01524302

Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority TrialPHASE4

UNKNOWN · via Levofloxacin · NCT02901288

Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis.PHASE2

COMPLETED · via Levofloxacin · NCT03201796

The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV InfectionPHASE3

COMPLETED · via Levofloxacin · NCT00001033

Efficiency of Antibacterial Prophylaxis (Levofloxacin) in Azacitidine Treated PatientsPHASE3

COMPLETED · via Levofloxacin · NCT03594149

Efficacy of a Short-term Sequential Therapy Versus Intravenous Standard Treatment for Patients With Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.PHASE3

TERMINATED · via Levofloxacin · NCT01875263

Efficacy of Two-week Therapy With Levofloxacin-based Concomitant Regimen Versus Levofloxacin-based Sequential Regimen for Helicobacter Pylori Infection in Syrian Population: a Prospective Single-center Randomized Controlled TrialPHASE4

NOT_YET_RECRUITING · via Levofloxacin · NCT06065267

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori TreatmentPHASE4

UNKNOWN · via Levofloxacin · NCT03139253

Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical CystectomyPHASE4

COMPLETED · via Levofloxacin · NCT04502095

A Phase IV Comparative Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial SinusitisPHASE4

COMPLETED · via Levofloxacin · NCT00645073

Local Antibiotic Delivery for Community Acquired Pneumonia - Pilot Study (LANDCAP1)PHASE2/PHASE3

NOT_YET_RECRUITING · via Levofloxacin · NCT06859450

Pathogenicity of Enteroaggregative E. Coli in Adult Volunteers; Dose-Escalation StudyPHASE1

TERMINATED · via Levofloxacin · NCT00362869

Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia With Lobar Consolidation or Pleural Effusion in ChildrenPHASE4

UNKNOWN · via Levofloxacin · NCT02618057

Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian PopulationPHASE4

UNKNOWN · via Levofloxacin · NCT02693574

Antibiotic Susceptibility-based Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy: a Prospective Clinical TrialPHASE4

COMPLETED · via Levofloxacin · NCT03708848

Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment：a Randomized Clinical TrialPHASE4

COMPLETED · via Levofloxacin · NCT02935010

Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke: A Randomized Controlled Clinical TrialNA

RECRUITING · via Levofloxacin · NCT05799326

A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired PneumoniaPHASE4

COMPLETED · via Levofloxacin · NCT00035347

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem CellsPHASE2/PHASE3

UNKNOWN · via Levofloxacin · NCT00215007

Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration FactorsPHASE4

UNKNOWN · via Levofloxacin · NCT00752947

A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Antibacterial Prophylaxis for Prevention of Infections in Azacitidine Treated Myelodysplastic Syndrome Patients.PHASE3

COMPLETED · via Levofloxacin · NCT02981615

An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract InfectionsPHASE4

UNKNOWN · via Levofloxacin · NCT03160807

ClinicalTrials.gov via the drug-target graph.

What's happening now

28

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2024-09-20

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  2. Label change2024-09-20

    Label change: LEVOFLOXACIN (ANDA200560)

    fda · regulatory · fda · via Levofloxacin

  3. Label change2023-06-21

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  4. New publication2019-07-18
    Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.

    Journal of neuroinflammation · 2019 · 419 citations · Europe PMC · via Levofloxacin

  5. Label change2019-05-03

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  6. Label change2019-05-03

    Label change: LEVOFLOXACIN (ANDA200560)

    fda · regulatory · fda · via Levofloxacin

  7. Label change2019-04-17

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  8. Label change2019-04-17

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  9. Label change2019-04-17

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  10. Label change2019-04-17

    Label change: LEVOFLOXACIN (ANDA090722)

    fda · regulatory · fda · via Levofloxacin

  11. Label change2019-04-17

    Label change: LEVOFLOXACIN (ANDA200560)

    fda · regulatory · fda · via Levofloxacin

  12. Label change2018-10-18

    Label change: LEVOFLOXACIN (ANDA200560)

    fda · regulatory · fda · via Levofloxacin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.